Stylianos Panopoulos

Author

National and Kapodistrian University of Athens ORCID

Also Known As

S Panopoulos, S. Panopoulos, STYLIANOS T. PANOPOULOS, Stelios Panopoulos, Stylianos Panopoulos, Stylianos T Panopoulos, Stylianos T. Panopoulos

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

National and Kapodistrian University of Athens Laiko General Hospital of Athens Onassis Cardiac Surgery Center Athens State University Aristotle University of Thessaloniki

About

Stylianos Panopoulos is an author at National and Kapodistrian University of Athens specializing in medicine, public health, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	265
2	Public Health	4	4	79
3	Emergency Medicine	2	2	32
4	Epidemiology	2	2	47
5	Health Sciences	1	1	32

Stylianos Panopoulos

Publications

901

Citations

H-Index

Page 1

	Year	Citations
Cardiac Tissue Characterization and the Diagnostic Value of Cardiovascular Magnetic Resonance in Systemic Connective Tissue Diseases Sophie Mavrogeni, Petros P. Sfikakis, Elias Gialafos, Arthritis Care & Research	2013	77
Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study Antonis Fanouriakis, Christina Adamichou, Sofia Koutsoviti, Seminars in Arthritis and Rheumatism Autoimmune DiseaseSystemic Lupus ErythematosusSystemic Lupus Erythematosus TreatmentLupusSystemic Treatment	2018	77
Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases Charalampos Papagoras, G. Fragoulis, Nikoleta Zioga, Annals of the Rheumatic Diseases	2021	67
Mycophenolate Versus Cyclophosphamide for Progressive Interstitial Lung Disease Associated with Systemic Sclerosis: A 2-Year Case Control Study Stylianos Panopoulos, Vassiliki-Kalliopi Bournia, Georgia Trakada, Lung Autoimmune DiseaseInflammatory Lung DiseaseAdvanced Lung DiseaseImmunologySystemic Sclerosis	2013	65
The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial George Karamanolis, Stylianos Panopoulos, Konstantinos Denaxas, Arthritis Research & Therapy	2016	53
COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study G. Fragoulis, Vassiliki-Kalliopi Bournia, Eugenia Mavrea, Rheumatology International	2021	50
Beneficial effect of the 5‐HT<sub>1A</sub> receptor agonist buspirone on esophageal dysfunction associated with systemic sclerosis: A pilot study George Karamanolis, Stylianos Panopoulos, Anastasios Karlaftis, United European Gastroenterology Journal	2014	41
Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study Stylianos Panopoulos, Maria G. Tektonidou, Alexandros A. Drosos, Arthritis Research & Therapy	2018	39
Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus G. Fragoulis, Gerasimos Evangelatos, Nikolaοs Tentolouris, Therapeutic Advances in Musculoskeletal Disease	2020	38
Cardiovascular Magnetic Resonance Identifies High-Risk Systemic Sclerosis Patients with Normal Echocardiograms and Provides Incremental Prognostic Value George Markousis‐Mavrogenis, Vasiliki-Kalliopi Bournia, Stylianos Panopoulos, Diagnostics	2019	37

Page 1